Phase II clinical trials typically are single-arm studies conducted to decide whether an experimental treatment is sufficiently promising, relative to standard treatment, to warrant further investigation. Many methods exist for conducting phase II trials under the assumption that patients are homogeneous. In the presence of patient heterogeneity, however, these designs are likely to draw incorrect conclusions. We propose a class of model-based Bayesian designs for single-arm phase II trials with a binary or time-toevent outcome and two or more prognostic subgroups. The designs' early stopping rules are subgroup specific and allow the possibility of terminating some subgroups while continuing others, thus providing superior results when compared with designs that ignore treatment-subgroup interactions. Because our formulation requires informative priors on standard treatment parameters and subgroup main effects, and non-informative priors on experimental treatment parameters and treatment-subgroup interactions, we provide an algorithm for computing prior hyperparameter values. A simulation study is presented and the method is illustrated by a chemotherapy trial in acute leukemia.
INTRODUCTION
Phase II clinical trials are usually single-arm studies conducted to decide whether an experimental treatment, E, is sufficiently promising relative to a standard treatment, S, to be studied in a ACCOUNTING FOR PATIENT HETEROGENEITY IN PHASE II CLINICAL TRIALS   2803 large-scale randomized trial. Interim monitoring rules are usually employed to stop the trial early for futility, and to avoid giving an unacceptable number of patients an inferior treatment. Taylor et al. [1] provide a simulation-based rationale for conducting such single-arm trials, rather than randomizing, when there is substantial information on S. Numerous designs have been proposed for phase II trials [2] [3] [4] [5] [6] [7] . Several methods that use regression models to account for covariates in particular phase II settings have been proposed [8] [9] [10] . When the response probabilities in prognostic subgroups are exchangeable one can use a hierarchical Bayesian model [11] . In a setting where the assumptions required for using a hierarchical model are not appropriate, however, a general method for phase II trials that accounts for patient heterogeneity between prognostic subgroups is not currently available.
To see why such a method is needed, consider a trial including good (G) and poor (P) prognosis patients where the historical response probabilities with S (or their means under a Bayesian formulation) are S,G = 0.45 and S,P = 0.25. Suppose that an improvement of 0.15 within each subgroup is desired, that is, response probabilities E,G 0.60 and E,P 0.40 with E are targeted. Such a trial often is designed, based on either frequentist or Bayesian criteria, by conducting simultaneous but separate trials within the subgroups, using two separate sets of rules that stop the trial and declare E not promising within the G subgroup if E,G 0.60 is unlikely, and within the P subgroup if E,P 0.40 is unlikely. This approach is inherently flawed since, if an agent that does not provide an improvement in one subgroup is unlikely to provide an improvement in the other subgroup, then the design cannot exploit this fact since the data from the two subgroups are not combined in any way. A common alternative approach that does use the combined data is simply to ignore patient prognosis, assume average historical and targeted probabilities, say (0.45+0.25)/2 = 0.35 and (0.60+0.40)/2 = 0.50, and conduct a conventional single-arm trial. As an alternative, London and Chang [12] propose a stratified phase II design that adjusts for patient heterogeneity. However, these approaches are both flawed since, in the presence of treatmentsubgroup interactions, they lead to designs with very large false-positive error and false-negative error (FNR) rates within each subgroup.
In this article we present a Bayesian methodology for the design and conduct of single-arm phase II clinical trials with binary or time-to-event (TTE) outcomes that accounts for heterogeneity between patient prognostic subgroups when treatment-subgroup interactions are present. Our formulation generalizes the approaches of Thall and Simon [5] and Thall et al. [13] . In each case, we assume a regression model with linear term including treatment-subgroup interactions. Owing to the importance of specifying priors that accurately reflect knowledge about the standard treatment and patient prognosis, while also providing a design with good properties, we provide an algorithm for computing numerical values of the prior hyperparameters. We propose monitoring rules, which may be applied continuously, periodically or after successive cohorts of patients, that allow accrual to be terminated in some subgroups while continuing in the others. We employ computer simulation to calibrate design parameters in order to obtain a design having good frequentist operating characteristics. Our aim is to provide a practical methodology with a wide range of potential applications and provide free software for implementing the method.
In Section 2 we present the regression model underlying the method and provide an algorithm for prior specification. Section 3 defines the decision criteria. Section 4 presents the results of a simulation study comparing our method to three alternative methods. Section 5 describes an application of our method to a clinical trial in relapsed acute myeloid leukemia (AML) and we conclude with a discussion in Section 6.
PROBABILITY MODEL

A parametric likelihood
To account for patient heterogeneity in a parsimonious but reliable way, we assume K prognostic subgroups, identified by the categorical covariate Z ∈{0, 1, . . . , K −1}. Denote the subgroup membership indicators I (Z = k), for k = 0, 1, . . . , K −1. For t = S or E, we assume linear components of the form
denoting 0 = 0 for convenience. The kth element of
is the historical effect of subgroup k compared with the baseline subgroup 0, and the kth element of
is the E-versus-S treatment effect within subgroup k. The model parameter vector h = ( , b, s) is 2K -dimensional. In terms of the parameters, the purpose of the trial is to learn about s. We allow the treatment effects to differ between subgroups in order to provide a basis for a design that allows the trial to reach different conclusions within different subgroups. As we will show in Section 5, assuming the simpler model with a single E-versus-S effect, = 0 = 1 = · · · = K −1 , may lead to a design with very poor properties when treatment-subgroup interactions are present. The linear terms characterizing treatment and prognostic subgroup effects are summarized as follows:
The parametrization used here is critical to how well the method performs. It was chosen because it allows borrowing strength across subgroups and reflects the fact that much more is known a priori about the standard treatment. Specifically, by including the parameter in the linear term for all subgroups and the same j for each subgroup j, the model borrows information in a desirable way. One consequence of the parametrization is that the prior variance is smallest for the 'baseline' subgroup (subgroup 0, treated with S). It ensures that, within each subgroup j, the linear term S, j (h) of the treatment group S will have a smaller variance than E, j (h) for the corresponding experimental subgroup. This reflects the knowledge available, since much more is known about S. If an alternative parametrization were used where the prior for t,Z is normal with mean t,Z and variance 2 t,Z , then there would be no borrowing of information between the subgroups and one would effectively be conducting separate trials for each subgroup.
This formulation accommodates trials with either binary or TTE outcomes. For the binary case, denoting the treatment response indicator by Y , we assume the response probabilities t,
Denoting the data on the first n patients in the trial by 
For many applications with TTE outcomes, it is reasonable to assume exponentially distributed event times with means E(Y |t, Z , h) = e t,Z (h) , so that the pdf and survival functions are
To facilitate exposition, we will present and illustrate the method in the binary outcome case. Modifications needed to deal with TTE outcomes will be described in Section 6.
Establishing priors
To reflect prior knowledge about S and the effects of patient prognosis, we assume an informative prior on ( , b). In contrast, since little is known about the effects of E at the start of the trial, to ensure that the trial design is ethical and its results persuasive, no undue information should be introduced into the prior for E. We therefore assume a vague prior on s. This generalizes the approach of Thall and Simon [5] , who dealt with the homogeneous case with two response probabilities, E and S , assuming beta priors. In the present regime, for tractability we assume normal priors on all parameters: 
), and the vector of all 4K hyperparameters by w = (w , w 2 ). When applying Bayesian methods to conduct small-to moderate-sized clinical trials with outcome-adaptive decision rules, the numerical values of the hyperparameters are very important because they may substantively affect the decisions. Since the prior on ( , b|w) is informative but the prior on (s|w) is non-informative, we provide an algorithm for specifying numerical values of w that reflect these general requirements.
In some Bayesian models, there is a direct link between the prior hyperparameter values and a putative number of patients on whom the prior is based, i.e. its effective sample size (ESS). For our model, there is no clear link between w and such a prior ESS. Since the ESS of the standard Beta(a, b) distribution is a +b, we will exploit this to determine w by matching prior moments of the t, j (h)'s to those of specified Betas. To do this, we first impose the K constraints E{ E, j (h)}= E{ S, j (h)} for j = 0, . . . , K −1, so that the prior expected response rate of E equals that of S within each prognostic subgroup. These constraints are only valid for superiority trials and may be too optimistic for non-inferiority trials. As an alternative, one could impose the K constraints E{ E, j (h)}=ˆ E, j = E{ S, j (h)}− j , for example, one may use j = 0.05 to 0.10, for j = 0, . . . , K −1, so that the prior expected response rate of E is less than that of S within each prognostic subgroup. For each t and j, let f t, j ( p), 0 p 1, denote the prior density on t, j (h) induced by the prior on h. Given the above constraints on the mean probabilities, we determine w by matching the first two moments of each f t, j to those of a corresponding beta distribution, Beta(a t, j , b t, j ), with pdf denoted by f * t, j , having mean a t, j /(a t, j +b t, j ) and ESS a t, j +b t, j . We assume that estimates of the historical mean response rate and the number of historical patients in each subgroup are available for S, denoted byˆ S, j and N S, j , respectively, for
That is, we assume that these values may be computed from informative priors on the S, j (h)'s.
Let N E, j denote the desired prior ESS for the distribution of E, j (h). Given these values, we will use the following algorithm to determine w.
Algorithm for determining prior hyperparameters
Step 1:
Step 2: Find ( , 2 ) to minimize
Step 3:
Step 5:
) from Steps 2 and 3, for each j = 0, . . . ,
The algorithm exploits the facts that, given Step 1, f S,0 depends on w only through ( , 2 ); given Steps 1 and 2, for each
; and given
). The minimizations in Steps 2, 3, and 5 are carried out using the simplex algorithm of Nelder and Mead [14] . To reflect prior uncertainty about E in Step 5, reasonable values for N E, j are . Although the algorithm equates the prior mean response rates for S and E within subgroups, alternatively one may assume either more skeptical or more optimistic prior means for the E, j (h)'s. For example, if the more optimistic targetsˆ S, j + j with all j >0 are desired, e.g. j = j or j /2, then these values would be used as the prior means E{ E, j (h)} and in place ofˆ S, j in Steps 4 and 5 of the algorithm for determining w.
Computing posteriors
Let denote the K × K diagonal matrix with diagonal elements equal to w 2 . Combining the likelihood and priors from the previous sections, the posterior of h after observing D n is
where X(K)=I(Z=K) and we denote Typically, E must provide evidence of a response rate greater than that of S to be considered for a randomized phase III study. Formally, in subgroup j, E must provide a specified improvement j over S. We thus apply the subgroup-specific early stopping rules
where D n denotes the currently available data, and each decision cut-off p j is a fixed lower probability cut-off, usually in the range of 0.01-0.10. In practice, each p j may be calibrated to obtain a pre-specified FNR, defined as the probability of stopping the trial early for futility in subgroup j when the fixed 'true' value of E, j , denoted by true E, j , equals the fixed target E{ S, j (h)}+ j . The FNR corresponds to the type II error probability of a frequentist hypothesistest-based design. These rules may be applied continuously, periodically, or after successive cohorts of patients. An important property of our proposed method is that, because we allow treatmentsubgroup interactions, accrual may be stopped within one subgroup but continue in another. Using these rules with posterior quantities computed under regression model (1), the method borrows strength between subgroups. Our simulations will demonstrate the advantages of this approach over simpler methods that ignore treatment-subgroup interactions, or that do not assume a regression model, or that ignore patient subgroups entirely.
SIMULATION STUDIES
Although there are many phase II clinical trial designs, in order to fairly evaluate our method while focusing on the advantages of accounting for between-subgroup heterogeneity, we will compare it with three simpler versions of our design. All four methods are based on Bayesian models and use early stopping rules constructed to be as similar as possible to ensure comparability. Since our proposed method accounts for subgroups and, moreover, treatment-subgroup interactions, we denote it by S-TI for brevity. The first simplified method, S-NTI, assumes that there are no treatment-subgroup interactions, with the underlying regression model simplified by assuming
The second simplification, SEP, is to simultaneously conduct K separate trials, one within each subgroup, without using a regression model to borrow strength. The third simplification, NS, is to assume that there are no subgroup effects and conduct one trial. Since SEP does not borrow strength between subgroups and conducts separate trials within subgroups, we assume independent beta-binomial models within subgroups, with t, j (h) ∼ Beta(a t, j , b t, j ) for each j = 0, 1, . . . , K −1 and t = S, E. For NS, we also assume beta-binomial models, but now there are only two Beta distributions, E ∼ Beta(a E , b E ) and S ∼ Beta(a S , b S ), as in Thall and Simon [5] . To evaluate the designs over a realistic range of cases, we present the results of two simulation studies, one with K = 2 subgroups and another with K = 4. While each design's decision boundaries are computed based on a Bayesian model that regards the parameters as random, we evaluated each design's behavior over a range of fixed values of true E,0 , . . . , true E,K −1 . Since patient outcomes are rarely observed immediately, we assumed that there is one month from the start of treatment to the evaluation of response, with patients arriving at a rate of 30 per year according to a Poisson process, distributed equally among the subgroups. To ensure comparability, all four methods were implemented using a total maximum sample size of 100 and cohorts of 10 patients, with the data currently available when patients 11, 21, etc. arrived used to compute the stopping criteria.
To compute (D n , h, j, j ), denoted for brevity byˆ , in the S-TI and S-NTI designs, we sampled the posterior and calculated E, j (h) and S, j (h) for each sampled h. For the MCMC sampling procedure, we implemented four parallel chains, with an initial burn-in of 5000 samples followed by an additional 25 000 samples that were retained for computingˆ for each chain. To ensure convergence, we monitored the potential scale reduction [15] , and if this value was greater than 1.15 we obtained an additional 25 000 samples for each chain. Since the sampling procedure can be very time consuming andˆ must be computed repeatedly during each simulated trial, we stored theˆ values using a method similar to Wathen and Christen [16] . Storedˆ values corresponding to previously simulated data that matched the current data were retrieved to increase the speed of the simulations. In particular, using storedˆ values greatly increases the speed of the process of calibrating p j in (3) to obtain a pre-specified FNR. Sinceˆ must be computed and stored for many D n , once the valuesˆ are stored for an initial p j it becomes likely that much of the time-consuming MCMC sampling is avoided on all subsequent runs when calibrating p j , thus substantially increasing the speed of the simulations.
Two prognostic subgroups
In the first simulation study we assumed K = 2 subgroups, with j = 0 for Poor (P) and j = 1 for Good (G) prognosis. Since SEP conducts two separate trials in this case, for this design a maximum of 50 patients were enrolled in each trial. We used the same targeted improvement for both subgroups, 0 = 1 = 0.15. All designs were calibrated to have nominal FNR = 0.10, depending on the design's assumptions. For the S-TI and S-NTI designs, this meant that when true E, j = E{ S, j (h)}+ j the trial should declare E inferior (reject E) at most 10 per cent of the time within subgroup j, regardless of the true response rate in the other subgroup. For the SEP and NS designs, each of the K designs using SEP and the single design using NS had FNR = 0.10. The priors for all four methods were calibrated to be equivalent to having observed 100 historical patients on S (N S,0 = N S,1 = 100) and one patient on E (N E,0 = N E,1 = 1). For the S-TI, S-NTI, and SEP designs the prior means were E{ E,0 (h)}= E{ S,0 (h)}= 0.25 and E{ E,1 (h)}= E{ S,1 ( )}= 0.45. Since NS ignores subgroups the single prior mean was assumed to be 0.35, the average of the two subgroups, and thus for the NS method a priori S (h) ∼ Beta(35, 65) and E (h) ∼ Beta(0.35, 0.65), with the subscript j omitted because NS ignores subgroups. For SEP, we assumed S,0 (h) ∼ Beta(25, 75), E,0 (h) ∼ Beta(0.25, 0.75), S,1 (h) ∼ Beta(45, 55) and E,1 (h) ∼ Beta(0.45, 0.55). Using each of the four methods, we simulated the trial 5000 times under each of the four scenarios. The results are summarized in Table I .
In the 'treatment-subgroup interaction' Scenario 1, E achieves the targeted improvement in the G subgroup but not in the P subgroup. Thus, given desired FNR = 0.10, a design should reject E at most 10 per cent of the time in the G group but terminate accrual with reasonably high probability in the P subgroup. Both S-TI and SEP do this, although SEP has a smaller stopping probability for the P subgroup (0.65 versus 0.73 for S-TI) due to the fact that SEP does not borrow strength between subgroups. In sharp contrast, although S-NTI and NS both are constructed to control FNP = 0.10, due to the facts that S-NTI ignores treatment-subgroup interactions and NS ignores subgroups entirely, both of these designs have greatly inflated FNP values in the G subgroup, 0.47 with S-NTI and 0.42 with NS, as well as much smaller stopping probabilities in the P subgroup, 0.50 with S-NTI and 0.42 with NS. The clear messages here are that either ignoring patient heterogeneity or accounting for patient subgroups but not accounting for possible treatment-subgroup interactions greatly increases the risks of missing an actual treatment advance in a subgroup and of wrongly concluding that a treatment advance exists in a subgroup where it does not. The same messages are given by Scenario 2, where E achieves the targeted improvement in the P subgroup but not in the G subgroup. Another important advantage of the S-TI design is that, because it reliably controls both the FNRs and false-positive rates within subgroups, in the presence of treatment-subgroup interaction S-TI allocates a much larger number of patients to the subgroup where there is an actual treatment advance. For example, in Scenario 1 on average 64 patients are treated in the G subgroup by S-TI, compared with 38 with either S-NTI or NS and 47 with SEP. Thus, S-TI not only maintains the nominal FNR within subgroups but also uses patient resources much more effectively.
In the 'no treatment-subgroup interaction' Scenario 3, E achieves the targeted improvement in both the G and P subgroups and all four methods achieve the nominal 0.10 FNR. In the worst-case Scenario 4, where there is no improvement over S in either subgroup, all four methods have high probabilities of stopping the trial early, with much higher values 0.93 for S-NTI and 0.86 for NS, compared with 0.76-0.78 for S-TI and 0.65 for SEP. Given the very poor performance of S-NTI and NS in the presence of treatment-subgroup interactions, however, the larger stopping probabilities in Scenario 4 hardly make these methods desirable in situations where a treatment-subgroup interaction is likely. The smaller stopping probability with S-TI compared with the simpler S-NTI and NS methods in Scenario 4 is the price that is paid for its greatly superior performance when treatment-subgroup interactions are present.
To compare the four designs over a wider range of true E,0 and true E,1 values, for the null response rates 0.25 in P and 0.45 in G, we simulated cases with true E,1 = 0.60, the targeted improvement for Figure 1 (a) and for the P subgroup in Figure 1(b) . These figures may be interpreted as varying the amount of treatment-subgroup interaction, with the 'no interaction' case corresponding to the values where true E,0 = 0.40. Figure 1 (a) illustrates how poorly both S-NTI and NS perform, since nominally all curves should equal 0.10 for all values of true E,0 . In Figure 1 
Four prognostic subgroups
For a simulation study with K = 4 subgroups, we assumed a maximum sample size of 200 patients so that the per-subgroup sample sizes would be comparable to those in the simulations for Table II Table II . In Scenario 1, E achieves the targeted improvement in subgroups 2 and 3 but not in 0 or 1. Thus, it is desirable to have small rejection rates for E in subgroups 2 and 3 but large rates in 0 and 1. While both S-TI and SEP maintain the FNR = 0.10 within subgroups 2 and 3, S-NTI incorrectly rejects E 64 and 70 per cent of the time for groups 2 and 3, respectively, and NS incorrectly rejects E 64 per cent of the time for both subgroups. It thus appears that the probability of S-NTI and NS incorrectly stopping the trial and rejecting E in subgroups where E actually provides an advance over S increases substantially as the number of subgroups increases. In subgroup 0, S-TI has the largest chance of correctly rejecting E, 75 per cent compared with 74, 64 and 65 per cent for S-NTI, NS and SEP, respectively. In subgroup 1, all methods have approximately the same chance of rejecting E. In this case, S-TI reliably detects that E has not met the targeted improvement in subgroups 0 and 1 and terminates patient accrual to these groups, consequently allowing more patients in subgroups 2 and 3 to be treated with an effective treatment. Thus, the substantive conclusions are the same as those for the case K = 2, but the advantages of S-TI over the other methods are greater for K = 4. In Scenario 2, E achieves the targeted improvement in subgroups 0 and 3 but not in 1 or 2. The rest of the results are substantively similar to those of Scenario 2.
In Scenario 3, E only achieves the targeted improvement in subgroup 3. While both S-TI and SEP maintain FNR = 0.10 in subgroup 3, S-NTI and NS incorrectly reject E in this subgroup 92 and 90 per cent of the time, respectively. Since the stopping probabilities in subgroups 0, 1 and 2 with S-TI uniformly dominate those of SEP, this scenario provides an extremely strong motivation for accounting for subgroups and treatment-subgroup interaction.
In Scenario 4, E achieves the targeted improvement in all subgroups and thus, by design, all four methods have a 0.10 FNR. In Scenario 5, E fails to achieve the targeted improvement in all subgroups and thus it is desirable for a design to reject E in all subgroups with high probability. Because S-NTI and NS do not include a treatment-subgroup interaction, both procedures combine the information for the subgroups and thus, in this case, are nearly certain to stop early and reject E. However, S-TI has subgroup-specific stopping probabilities ranging from 0.76 to 0.83 in this case. 
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'ara-C'), whereas patients with CRD1 1 year have second CR rates of about 45 per cent when treated similarly. The most effective therapy for relapsed AML appears to be an allogeneic stem cell transplant from an HLA-matched donor (allotx). Since allotx is not feasible for many patients, there is a need to develop new chemotherapy regimens for patients with AML in first relapse. Gemtuzumab ozogamycin (GO) is a combination of an antibody against CD33, an antigen found on the surface of AML cells, and a toxin. The antibody is hypothesized to direct the toxin to the AML cells rather than their normal counterparts. Although approved by the FDA for treatment of AML in first relapse, GO is only slightly more effective than ara-C in this circumstance. However, decitabine, an agent that is believed to allow re-expression of genes that are silenced by AML cells, has been found to increase sensitivity to GO in AML model systems. This finding provides the basis for the current trial, which administers decitabine for 5 days, with GO given on day 5. We obtained historical data on 171 AML patients in first relapse enrolled between 1994 and 2003 at M.D. Anderson Cancer Center. The empirical overall probability of response to historical treatment was 0.21. However, upon classifying patients by CRD1 as either poor prognosis (P), if CRD1 < 52 weeks, or good prognosis (G), if CRD1 52 weeks, the 118 (69 per cent) patients in the P subgroups had a response rate of 0.11 and 53 (31 per cent) patients in the G subgroup had a response rate of 0.43.
A typical phase II study would employ a Simon's 2-stage (S2S) design [4] and would assume patient homogeneity. However, based on the heterogeneity seen in the historical data we applied our proposed design, using P-versus-G as a binary prognostic variable. The goal of the study is to determine if GO can increase the response rate by 0.15 in the G subgroup, from 0.43 to 0.58 and 0.20 in the P subgroup, from 0.11 to 0.31. Using a null response probability equal to the overall Table III . Simulation results for a trial with two prognostic subgroups, P (first CR duration 52 weeks) and G (first CR duration >52 weeks), for 2-stage (N max = 40) and multi-stage (N max = 80). 
